Mar 18, 2020
Novartis Recalls 100 mg Sandimmune and Neoral Prescription Drug Blister Packages Due to Failure to Meet Child-Resistant Packaging Requirement; Risk of Poisoning
Mar 18, 2020
Novartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirements
Feb 03, 2020
RegeneRx Partner Updates on Phase 3 Dry Eye Trial
Nov 04, 2019
Kantum Pharma Founder to Present Preclinical Data Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury at the American Society of Nephrology Annual Meeting
Oct 22, 2019
Organ Transplant Immunosuppressant Drugs Market Worth $5.88 Billion by 2026: Grand View Research, Inc.
Mar 26, 2019
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome
Sep 06, 2018
NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan
May 10, 2018
Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease
May 02, 2018
Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018
Oct 19, 2017
Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®
Oct 16, 2017
U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents
Oct 12, 2017
Allergan Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation with InnoPharma, Inc.
Oct 12, 2017
Calcium Lets T Cells Use Sugar to Multiply and Fight Infection
Aug 28, 2017
Allergan Announces Settlement of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation with Famy Care